• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    PetMed Express Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    6/16/25 8:37:04 AM ET
    $PETS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $PETS alert in real time by email
    pets-20250616
    0001040130false00010401302025-06-162025-06-16


     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the
    Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): June 16, 2025
     
    PETMED EXPRESS, INC.
    (Exact Name of Registrant as Specified in its Charter)
     
     
     
     
     
      
    Florida
     
    000-28827
     
    65-0680967
    (State or Other Jurisdiction
     
    (Commission
     
    (IRS Employer
    of Incorporation)
     
    File Number)
     
    Identification No.)
         
     
    420 South Congress Avenue, Delray Beach, Florida
     
    33445
    (Address of Principal Executive Offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: (561) 526-4444
     
    N/A
    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
          ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
          ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
          ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
          ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.001 par value PETSNASDAQ Global Select Market
    Preferred Stock Purchase RightsN/A
    NASDAQ Global Select Market
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
     
              Emerging growth company      ☐             
     



    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ 




    Item 2.02 Results of Operations and Financial Condition.
    On June 16, 2025, PetMed Express, Inc. (the “Company”) issued a press release announcing preliminary financial results for the fourth quarter and fiscal year ended March 31, 2025. These preliminary financial results are unaudited, based on currently available information and do not present all necessary information for a complete understanding of the Company’s financial condition as of March 31, 2025, or its results of operations for the fourth quarter and year ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.
    The information furnished in this Item 2.02 on this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, regardless of any general incorporation language in such filing.

    Item 9.01. Financial Statements and Exhibits.

    (d)    Exhibits

    Exhibit No.

    Description
    99.1
    Press Release.
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)



        

    Cautionary Note Regarding Forward-Looking Statements

    This Current Report on Form 8-K, including Exhibit 99.1 furnished herewith, contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements. Words such as “may,” “could,” “expect,” “project,” “outlook,” “strategy,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “strive,” “goal,” “continue,” “likely,” “will,” “would” and other similar words and expressions are intended to signify forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations regarding the timing of the filing of its Form 10-K for the fiscal year ended March 31, 2025, as well as the Company’s preliminary unaudited financial results disclosed. Forward-looking statements are based on the Company’s current expectations and assumptions regarding future events, which are subject to risks and uncertainties. Actual results could differ materially from those anticipated due to a number of factors, including but not limited to, the completion of the audit of the Company’s financial statements, the identification of material adjustments during the audit process, and other risks described from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2024, as well as other subsequent filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Current Report on Form 8-K and should not be relied upon as representing the Company’s views as of any subsequent date. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.





    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
    PETMED EXPRESS, INC.
    Dated: June 16, 2025
    /s/ Robyn D’Elia
    Robyn D’Elia
    Chief Financial Officer and Treasurer


    Get the next $PETS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PETS

    DatePrice TargetRatingAnalyst
    5/25/2023$20.00Buy
    Lake Street
    1/25/2022$25.00 → $21.00Underweight
    Morgan Stanley
    1/20/2022$32.00Neutral → Buy
    Sidoti
    11/18/2021$25.00Underweight
    Morgan Stanley
    10/1/2021$28.00Hold
    Jefferies
    8/5/2021$22.00Underperform
    Credit Suisse
    More analyst ratings